Assessing the Effect of Pomalidomide or Carfilzomib Treatment on Patient-Reported Outcomes Among Patients With Relapsed/Refractory Multiple Myeloma

被引：0
|
作者：
Gupta, Shaloo [1 ]
Clancy, Zoe [2 ]
Copher, Ronda [2 ]
Rosenberg, Aaron Seth [3 ]
机构：
[1] Kantar, New York, NY USA
[2] Celgene Corp, Summit, NJ USA
[3] Univ Calif Davis, Comprehens Canc Ctr, Div Hematol & Oncol, Sacramento, CA 95817 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
Multiple myeloma; Patient Reported Measures; Pomalidomide;
D O I：
10.1016/j.clml.2019.09.443
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SP-117
引用
收藏
页码：E268 / E269
页数：3
相关论文
共 50 条
  • [41] Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study
    Cardellino, Anna
    Correll, Julia R.
    Martin, Mona
    Gorsh, Boris
    Sapra, Sandhya
    Popat, Rakesh
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [42] Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series
    Richter, Joshua
    Biran, Noa
    Duma, Narjust
    Vesole, David H.
    Siegel, David
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (02) : 246 - 251
  • [43] Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma
    Chen, Miao
    Yu, Hong
    Liu, Aijun
    Wang, Wei
    Qin, Xiaoqi
    Li, Ziping
    Ma, Yanping
    Chen, Wenming
    Fu, Rong
    Zhuang, Junling
    BLOOD, 2024, 144 : 7038 - 7038
  • [44] Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan
    Jerry Teng, Chieh-Lin
    Yeh, Su-Peng
    Chen, Tsai-Yun
    Hung, Yu-Chin
    Lin, Yun-Chu
    Li, Sin Syue
    Wang, Ming-Chung
    Huang, Shang-Yi
    HEMATOLOGY, 2024, 29 (01)
  • [45] Patient-Reported Outcomes (PROs) From the Phase 3 ARROW Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)
    Moreau, Philippe
    Kumar, Shaji
    Boccia, Ralph
    Iida, Shinsuke
    Goldschmidt, Hartmut
    Cocks, Kim
    Zahlten-Kumeli, Anita
    Yucel, Emre
    Panjabi, Sumeet
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S240 - S240
  • [46] A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
    Watanabe, Takashi
    Tobinai, Kensei
    Matsumoto, Morio
    Suzuki, Kenshi
    Sunami, Kazutaka
    Ishida, Tadao
    Ando, Kiyoshi
    Chou, Takaaki
    Ozaki, Shuji
    Taniwaki, Masafumi
    Uike, Naokuni
    Shibayama, Hirohiko
    Hatake, Kiyohiko
    Izutsu, Koji
    Ishikawa, Takayuki
    Shumiya, Yoshihisa
    Kashihara, Tomohisa
    Iida, Shinsuke
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (05) : 745 - 756
  • [47] Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment
    Matsue, Kosei
    Sunami, Kazutaka
    Matsumoto, Morio
    Kuroda, Junya
    Sugiura, Isamu
    Iwasaki, Hiromi
    Chung, Weiyuan
    Kuwayama, Shigeki
    Nishio, Mitsufumi
    Lee, Kim
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (01) : 122 - 130
  • [48] Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials
    Zou, Yandun
    Ma, Xiaoyan
    Yu, Haiying
    Hu, Chunling
    Fan, Limei
    Ran, Xuehong
    ONCOTARGET, 2017, 8 (24) : 39805 - 39817
  • [49] Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes
    Richardson, Paul G.
    Harvey, R. Donald
    Laubach, Jacob P.
    Moreau, Philippe
    Lonial, Sagar
    San-Miguel, Jesus F.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (01) : 35 - 48
  • [50] Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
    De Novellis, Danilo
    Derudas, Daniele
    Vincelli, Donatella
    Fontana, Raffaele
    Della Pepa, Roberta
    Palmieri, Salvatore
    Accardi, Fabrizio
    Rotondo, Francesco
    Morelli, Emanuela
    Gigliotta, Emilia
    Roccotelli, Daniela
    Marano, Luana
    Barone, Maria Lucia
    Cetani, Giusy
    Esposito, Daniela
    Lazzaro, Antonio
    Delle Cave, Giuseppe
    Serio, Bianca
    Morini, Denise
    Porrazzo, Marika
    Urciuoli, Eleonora
    Masucci, Chiara
    Fanelli, Fulvia
    Rizzo, Michela
    Arcamone, Manuela
    Trastulli, Fabio
    Rocco, Stefano
    Leone, Aldo
    Bianco, Rosario
    Salvatore, Flavia
    Idato, Aurora
    Sicari, Maria
    Tosi, Patrizia
    Rascato, Maria Gabriella
    Di Perna, Maria
    Falcone, Antonietta Pia
    Morello, Lucia
    Carlisi, Melania
    Svanera, Gino
    Annunziata, Mario
    Frigeri, Ferdinando
    Califano, Catello
    Carella, Angelo Michele
    Marcacci, Gianpaolo
    Pane, Fabrizio
    Risitano, Antonio Maria
    Giudice, Valentina
    Botta, Ciro
    Selleri, Carmine
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (01) : 105 - 114
12345